Xencor Inc. (XNCR) Long-Term Debt to Capital Ratio

Xencor, Inc. - graphic logo of issuer XNCR

Xencor, Inc. (XNCR) creates innovative protein structures using its proprietary antibody optimization system. The company generates revenue by providing its developments to pharmaceutical behemoths, receiving stable royalties. Income is based on upfront payments for access to technologies targeting tumors and autoimmune pathologies. The current figure is 0.26. This chart of the market price illustrates the asset value dynamics for this developer.

Long-Term Debt to Equity: Xencor, Inc. (XNCR) for 07/04/2022 - 10/30/2026

Analytical breakdowns for Xencor, Inc.

- market price and analyst price targets:
Market Price Xencor Inc|XNCR - Price Target Chart
- market capitalization details:
Market Capitalization Xencor, Inc.|XNCR - Enterprise Value
- issuer book value statistics:
Accounting Value per Share Xencor|XNCR - Company Book Value|Market-to-Book Ratio xencor.com|XNCR - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Xencor, Inc.|XNCR - Long-Term Debt to Equity|Current Liabilities to Capital xencor.com|XNCR - Company Aggregate Debts|Debt to Net Assets Xencor, Inc.|XNCR - Company Long-Term Liabilities|Short-Term Debt Xencor|Intermediate Coverage Ratio xencor.com
- company profitability and valuation multiples indicators:
XNCR - Net Profit
Summary company analysis:XNCR - Xencor Inc
Brand item of Xencor Corp

It is critically important for Xencor, Inc. (XNCR) to maintain financial autonomy while the peak development of XmAb bispecific antibodies requires colossal expenditures for clinical trials. Analyzing the ratio of long-term debt to equity allows for the filtering of market noise, assessing the real stability of the balance sheet and protection against delisting by comparing long-term liabilities with the company's base capital.

Competing companies

Long-Term Liabilities to Capital ImmunityBio Inc IBRX|Long-Term Debt to Equity Immunocore PLC (IMCR)|Janux Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RCUS (Arcus Biosciences, Inc.)|ZYME - Long-Term Debt to Equity Ratio|TNGX - Long-Term Debt to Equity|Long-Term Liabilities to Capital Iovance Biotherapeutics Inc|Immatics Corp (IMTX) - Long-Term Debt to Equity|CMPX (Compass Therapeutics Corp) - Long-Term Debt to Equity|Long-Term Debt to Equity Replimune Group, Inc.|Long-Term Liabilities to Capital lyell.com LYEL|Long-Term Debt to Capital IPHA|pyxisoncology.com (PYXS) - Long-Term Indebtedness to Equity|Compugen - Long-Term Debt to Equity Ratio|IO Biotech Inc. (IOBT) - Long-Term Liabilities to Capital|STRO: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient INKT (minktherapeutics.com)|HOWL: Long-Term Debt to Capital|IMMX - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ALX Oncology Holdings|Long-Term Debt to Equity Ratio cuebiopharma.com (CUE)|Long-Term Debt to Equity PDS Biotechnology (PDSB)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|MAIA Biotechnology, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Liminatus Pharma Inc. LIMN|LVTX - Long-Term Debt to Equity|NXTC (NextCure Corporation) - Long-Term Debt to Capital Ratio|leaptx.com (LPTX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Intensity Therapeutics, Inc. (INTS)|Long-Term Debt to Equity Ratio SNSE|TOVX - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio GRTS (Gritstone bio, Inc.)|Long-Term Loans to Capital Ratio KA|Long-Term Debt to Capital NEXI (NexImmune, Inc.)|Long-Term Debt to Capital Coefficient TSBX|Vaccinex - Long-Term Debt to Capital|Long-Term Liabilities to Capital Harpoon Therapeutics Inc